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HUMAN HERPESVIRUS-7 AS A CAUSE OF EXANTHEMATOUS ILNESSES IN BELÉM, PARÁ, BRAZIL
Ronaldo B. FREITAS, Maria R. FREITAS, Consuelo S. OLIVEIRA & Alexandre C. LINHARES
SUMMARY
We screened sera from 370 patients suffering from exanthematous illnesses in Belém, North Brazil, for the presence of human
herpesvirus-7 (HHV-7) IgM and IgG antibodies. Samples were obtained from January 1996 to December 2002 and were processed
by a HHV-7-specific indirect immunofluorescence assay (IFA). HHV-7-specific IgM and/or IgG antibodies were found in 190 (51.4%)
of these patients, with similar prevalence rates (IgM+ and IgG+ subgroups taken together) for female and male subjects: 52.5% and
50.3%, respectively. Serological status as defined by IgG was identified in 135 (36.5%) patients. In 55 (14.9%) of the patients HHV-
7 IgM antibodies were detected. HHV-7 IgM- and- IgG antibody rates were similar (p > 0.05) when male and female subjects are
compared: 14.4% versus 15.3% and 38.1% versus 35.0%, respectively. Statistically significant difference (p = 0.003) was noted when
HHV-7-IgM-positive female and male patients aged 5-8 months are compared. Prevalence rates ranging from 4.6% (female, 5-8
months of age) to 93.3% (female, > 10 years of age) and 12.2% (male, 5-8 months) to 80.0% (male, 8-10 years of age) were noted in
the IgG- positive subgroups. A subgroup (n = 131) of patients with IgM or IgG HHV-7 antibodies were examined for the presence of
DNA using a polymerase chain reaction/nested PCR. Recent/active HHV-7 infection occurred at a rate of 11.0% (6/55) among
patients whose samples presented IgM+ specific antibodies. In a subgroup (n = 76) of patients with high HHV-7-IgG antibody levels
(titre > 1:160) DNA could not be detected in sera examined by PCR/nested PCR. Of the six recent/active infections, four subjects with
less than 1 year and two with 3 and 6 years of age, presented typical exanthem subitum (E.S), as defined by higher fever (> 38.0 ºC)
with duration of 24 to 72 hours, followed by a maculopapular skin rash. Our results underscore the need for searching HHV-7
infection in patients with exanthematous diseases, particularly those presenting with typical E.S. HHV-7 appears therefore to emerge
as a newly recognized pathogen of exanthem in our region.
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INTRODUCTION
Human herpesvirus-7 was first isolated by FRENKEL et al.15 from
activated CD4+ peripheral blood T cells of a healthy individual in
19902,20,23. It is currently known to belong to the β- herpesvirinae
subfamily2,24.
HHV-7 is ubiquitous and primary infection occurs mainly during
infancy between the ages of 2 to 5 years3,6,39, therefore later than that of
HHV-616. The exanthema subitum (E.S) is the commonest clinical
presentation of the HHV-7 infection in infancy and childhood1,8,17,31,34.
Serological evidence for primary HHV-7 infection has been obtained
from adult patients with pityriasis rosea14, aseptic meningitis24,42 and
chronic fatigue syndrome13. In addition to this, neurological disease in
children with E.S has been evidenced through the occurrence of febrile
convulsions and acute hemiplegia23,24,25,33,34,35. Childhood HHV-7 recurrent
fever has also been reported1. Recently, HHV-7 has been isolated from
saliva of healthy adults, indicating that salivary glands are a likely site
of HHV-7 replication38.
Studies on the seroprevalence for HHV-7 infection conducted in USA
yielded rates that exceed 85.0%11. In Japan41, seropositivity rates in
children aged 1 to 4 and 7 to 8 years were 45.0% and 40.0%, respectively.
Also in Japan, primary HHV-7 infection was estimated to occur in 10.2%
of patients with clinically diagnosed E.S, as reported by HIDAKA et
al.17. In a study conducted by BLACK et al.4 among Brazilian children
clinically diagnosed as measles and rubella, patients’ sera were negative
for antibodies to both viruses, but clearly seroconverted to HHV-6 and
HHV-7 with 20.0% and 8.0%, respectively.
In this study we report the occurrence of exanthematous illnesses
(most of which clinically diagnosed as E.S) associated with primary
HHV-7 infection in Belém, Pará, north Brazil.
MATERIAL AND METHODS
The study was conducted in Belém, Pará, Brazil between January
1996 and December 2002. A total of 370 blood samples were collected
from individuals presenting with exanthematous illnesses at the Virology
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Section of Instituto Evandro Chagas. These patients were selected from
an overall 2,550 individuals with exanthematous illnesses (high fever
and maculopapular skin rash) who tested negative for the following
agents: measles, rubella, Epstein-Barr virus, cytomegalovirus, parvovirus
B19, human herpesvirus-6 (HHV-6) and arboviruses (Mayaro,
Oropouche and dengue). Of the 370 individuals 181 were female and
189 were male, with ages ranging from 3 months to 68 years (mean age,
6 years). Blood samples were collected during acute phase of disease by
antecubital venepuncture. All sera were stored frozen at –20 ºC until
processed anonimously.
Detection of IgM- and- IgG antibodies to HHV-7 was made using a
commercially available immunofluorescence assay (IFA) manufactured
by STELLAR BIOSYSTEMS™ (Columbia, USA). This system includes
solid-phase multiple-spot slides coated with human lymphocytes infected
with HHV-7, as previously described36. Sera were tested at a (single)
dilution of 1:10 with previous removal of IgG fraction using
GullSORB™, Salt Lake City, Utah, USA. This ensures that no
interference will occur with rheumatoid factor. Tested samples were
regarded as HHV-7-IgM positive when a bright green fluorescent staining
could be noted in the infected cells of the screening dilution. The presence
of HHV-7 IgM antibody in the samples defined recent infection (the
cutoff values for negative and positive results for HHV-7 in sera were
less than 1:10 and 1:10, respectively).
A subgroup (n = 131) of subjects with IgM and/or high (> 1:160)
IgG antibodies level to HHV-7 were selected for DNA detection using
the polymerase chain reaction (PCR). This reaction was performed in
two steps, essentially as reported before18,37. A first amplification was
done using a mixture of external oligonucleotide primers (MK1 and
MK2), followed by a second amplification (nested PCR) that involved a
mixture of the internal primers MK3 and MK4. Each PCR reaction was
composed of a mixture including 1.5 mM MgCl2, 0.5 µM of each primer,
and 2.5 units of Taq DNA polymerase (INVITROGEN™) in the final
concentration. Thermal cycles were ran as follows: 1 initial cycle at
95 ºC for six min, 40 cycles of denaturation at 94 ºC for thirty seconds,
annealing at 50 ºC for thirty seconds, and extension at 72 ºC for thirty
seconds. A single final extension step at 72 ºC for ten minutes was
developed. HHV-7 active infection was defined as the presence of either
IgM or IgG antibodies plus the detection of viral DNA. Concurrently,
serological assays were used for the detection of both IgM and IgG
antibodies to rubella, measles, Epstein-Barr virus, cytomegalovirus,
parvovirus B19 and HHV-610,12,19,22,26,27. Serum specimens were also
assayed by conventional haemagglutination-inhibition (HI), as described
before29, for the detection of antibodies to Mayaro, Oropouche and
dengue viruses.
Statistical analysis was done with EPI-INFO software, version 6.0
(Atlanta, GA, USA). Comparison of rates between groups was made
with the Mantel-Haenszel chi-square test of association or, if assumptions
required for the chi-square test were not met, with Fisher’s exact test.
Siqnificance was defined as p < 0.05.
RESULTS
A total of 190 (51.4%) of the 370 patients had HHV-7-specific IgM
and/or IgG antibodies in their sera, whilst 180 (48.6%) subjects were
found to be IgM- and- IgG seronegative (Table 1). Similar rates of HHV-
7 antibodies (IgM and/or IgG) were noted for female and male subjects:
52.5% and 50.4%, respectively. Serological status as defined by the
presence of HHV-7 IgG antibodies was identified in 135 (36.5%) patients.
In addition, 55 (14.9%) of the 370 patients were found to be HHV-7
IgM- positive. Positivity rates for both female and male subjects were
compared [14.4% versus 15.3% (IgM+ subgroup) and 35.0% versus
38.1% (IgG+ subgroup)], but no significant differences (p > 0.05) were
observed. A significant difference (p = 0.003) was seen when female
and male IgM-positive subjects aged 5 to 8 months are compared.
Prevalence rates ranging from 4.6% (female, 5-8 months of age) to 93.3%
(female, >10 years of age) and 12.2% (male, 5-8 months of age) to 80.0%
(male, 8-10) were noted in the IgG-positive subgroups. The prevalence
rates increased across the 5 age-groups, if considered the IgM-positive
and IgG-positive subjects. The frequency of the recent/active HHV-7
infection was of 11.0% (6/55) among patients whose sera presented levels
of IgM-specific antibodies plus DNA detection (Table 1). Of these, four
subjects aged less than 1 year and two with 3 and 6 years presented
typical E.S. Figure 1 illustrates the nested-PCR displaying the amplified
HHV-7 DNA fragments and controls. This analysis included a negative
control (lane 1), a positive control (lane 2) and 5 serum samples shown
to be DNA-positive (lanes 3-7). No positive results were obtained from
Table 1
Detection of antibodies to HHV-7 in patients with exanthematous illness.
Belém, Brazil, 1996-2002
Serological status, n (%)
Age Sex Total* IgM+ IgG+ IgM-/IgG-
tested
Months
≤ 4 F 21 2(9.5) 5(23.8) 14(66.7)
M 16 3(18.7) 5(31.2) 8(50.0)
5-8 F 43(1) 11(25.6)a 2(4.6) 30(69.8)
M 49 2(4.1)b 6(12.2) 41(83.7)
9-12 F 55(2) 9(16.4) 19(34.5) 27(49.1)
M 55(1) 8(14.5) 12(21.8) 35(63.7)
Years
2-4 F 24(1) 1(4.2) 12(50.0) 11(45.8)
M 31 6(19.4) 17(54.8) 8(25.8)
5-7 F 15 3(20.0) 11(73.3) 1(6.7)
M 17(1) 6(35.3) 10(58.8) 1(5.9)
8-10 F 08 0(0) 6(75.0) 2(25.0)
M 05 1(20.0) 4(80.0) 0(0)
> 10 F 15 0(0) 14(93.3) 1(6.7)
M 16 3(18.7) 12(75.0) 1(6.3)
Subtotal F 181 26(14.4) 69(38.1) 86(47.5)
M 189 29(15.3) 66(35.0) 94(49.7)
Total 370 55(14.9)c 135(36.5)d 180(48.6)
* A total of 131 serum samples were screened by PCR/ nested PCR.
() Number of HHV-7 DNA detection; a vs b Significant difference between the
results (p = 0.003); c + d = 51.4% (overall seroprevalence rate).
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testing sera for potential pathogens other than HHV-7 - including HHV-
6 - that might be involved in etiology of the exanthematous illness.
DISCUSSION
Serological studies conducted in both temperate and tropical countries
have shown the wide distribution of HHV-7 infection, as well as its
association with cases of E.S, mainly in children above 3 years of age
and young adults1,3,8,9,11,17,31,34,38. Investigations conducted in USA11,38 and
Mexico21 presented rates of 85.0% and 98.0%, respectively, which are
higher than those found in our serosurvey (51.6%). Conversely, in Japan41
lower prevalence rates, 45.0% and 40.0% for subjects of 1-4 and 7-8
years of age, respectively, were observed. These data suggest that a
variation in seroprevalence rates may occur in the different geographical
areas. It is likely that methods of sample collection32, together with some
differences in the techniques41 used for the diagnosis of the HHV-7
infection may have accounted for such variable results.
It is noteworthy in our study that a decline in the seroprevalence
rates for HHV-7 antibodies occurred among individuals of ≤ 4 months
and 5-8 months if we consider the IgM-positive and IgG-positive. This
trend for a gradual decline in antibody levels may reflect the progressive
loss of the maternal antibodies11,41. This situation was not observed in
several other studies including one in USA11,38 that recorded such
occurrences in children aged above 3 years, after they had developed
primary HHV-6 infections7,8,11. In accordance with previous studies11,31,
this might be related to the persistence of protecting HHV-7 maternal
antibodies for longer than HHV-6 antibodies. This fact may explain the
occurrence of two primary HHV-7 infections among children aged 3
and 6 years in the present study. In spite of the four recent/active HHV-
7 infections observed in children with less of one year in our investigation,
49.0% to 64.0% of the individuals among 9-12 months, and 26.0% to
46.0% among 2-4 years examined, were still seronegative for the HHV-
7. In support to these findings we observed that prevalence rates increased
sharply as from two years of age onwards, being of 58.0% to 75.0% in
age 5-7 years and 75.0% to 93.0% in > 10 years of age if included those
subjects who were IgG-positive only. Analysis of these data leads us to
postulate that an epidemiological profile similar to ours was observed
mainly in USA and Japan, where primary HHV-7 infections appear to
occur later than that by HHV-68,38, therefore being regarded as the second
exanthematous illness during childhood32.
In this study the frequency of primary HHV-7 infection associated
with E.S was similar to that reported for Japan17, around 10.0%. Our
results showed that HHV-7 DNA detection in blood (serum) was lower
than those reported from other studies that used either saliva5,16 or
peripheral blood mononuclear cells13,37. It is worth to point out that saliva
and peripheral blood mononuclear cells are associated with sites of
persistence to the HHV-78,30,37, where a high virus DNA concentration is
expected. It is also worth underscoring the fact that detection of HHV-7
DNA in serum and plasma obtained during acute phase of disease is a
marker of primary infection28,36.
In our study the patients with primary HHV-7 infections presented
with clinical features resembling those of E.S, in general characterized
as clinically moderate. Symptoms included high fever and subsequent
maculopapular skin rash lasting 24 to 72 hours. Of note, such a typical
E.S is often associated with primary HHV-6 infections40 and, less
frequently, with HHV-7 infection. Severe neurological complications
due to invasion of the central nervous system, mainly those associated
with E.S, as demonstrated by other authors23,25,33,35, were not recorded in
the present study.
Our results suggest that HHV-7 infection should be sought in cases
of exanthematous illnesses affecting both children and adults in our region
and elsewhere. The fact that pathogens other that HHV-7 (including some
arboviruses) were ruled out as a likely cause for the exanthematous
diseases among our patients sustains our proposed causal relationship
between HHV-7 and E.S in our region. To our knowledge, these are the
first findings in North Brazil that provide evidence in support to the role
that HHV-7 might have as a cause of exanthematous illnesses during
childhood.
RESUMO
Herpesvírus humano-7 como causa de doença exantemática
em Belém, Pará, Brasil
Examinamos soros de 370 pacientes acometidos de doença
exantemática, selecionados em Belém, norte do Brasil, com o propósito
de se detectarem anticorpos IgM e IgG para o herpesvírus humano-7
(HHV-7). As amostras foram obtidas entre janeiro de 1996 e dezembro
de 2002 e, posteriormente, processadas utilizando-se a técnica da
imunofluorescência indireta (IFI). Taxas de anticorpos IgM e/ou IgG
foram encontradas em 190 (51,4%) desses pacientes. Observamos taxas
de prevalência similares para os sexos feminino e masculino com: 52,5%
e 50,3%, respectivamente. O “status” sorológico foi definido pela
presença de anticorpos IgG nos espécimes de 135 (36,5%) pacientes. A
par disso, em 55 (14,9%) dos 370 pacientes foram detectados anticorpos
IgM para o HHV-7. Taxas de anticorpos IgM e IgG para o HHV-7 foram
similares (p > 0.05) quando comparamos indivíduos do sexo feminino e
masculino: 14,4% versus 15,3% e 38,1% versus 35,0%, respectivamente.
Diferença estatisticamente significativa (p = 0,003) foi observada quando
comparamos as taxas de anticorpos IgM para o HHV-7 nos indivíduos
do grupo etário de 5-8 meses pertencentes ao sexo feminino e masculino.
Taxas de prevalência variando de 4,6% (masculino, 5-8 meses de idade)
a 93,3% (feminino, > 10 anos de idade) e 12,2% (masculino, 5-8 meses
Fig. 1 - Agarose gel electrophoresis of nested PCR- amplified HHV-7 DNA of 7 serum
samples, stained with ethidium bromide and photographed under U.V light. Lane 1, negative
control; lane 2, HHV-7 control; lanes 3-7, displays HHV-7 positive sera; M denotes molecular-
weight.
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de idade) a 80,0% (masculino, 8-10 anos de idade) foram observadas no
subgrupo positivo para IgG. Um subgrupo (n = 131) de pacientes com
anticorpos IgM ou IgG foi examinado quanto a presença de DNA para o
HHV-7 pela técnica da reação em cadeia da polimerase/ “nested” PCR.
Infecção recente/ativa para o HHV-7 ocorreu em 11,0% (6/55) dos
pacientes cujas amostras apresentaram anticorpos IgM específicos para
o HHV-7. Em um subgrupo (n = 76) de pacientes com altos níveis de
anticorpos IgG para o HHV-7 (título > 1: 160) não foi detectada a presença
de DNA em seus soros pelo PCR/ “nested” PCR. Entre as seis infecções
recentes/ativas, quatro indivíduos com menos de um ano e dois com 3 e
6 anos de idade apresentaram típico exantema súbito (E.S) definido por
febre elevada (> 38,0 ºC) com duração de 24 a 72 horas, acompanhando-
se de erupção cutânea maculopapular.
Nossos resultados ressaltam a necessidade de procurarmos a infecção
pelo HHV-7 em pacientes portadores de doença exantemática,
particularmente naquelas apresentações típicas de E.S. O HHV-7 parece
emergir como um novo patógeno associado a quadros exantemáticos
em nossa região.
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